Aldeyra director to step down at 2026 meeting

Aldeyra Therapeutics, Inc. reported that Board member Martin J. Joyce has decided not to stand for re-election at the company’s 2026 annual meeting of stockholders.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Aldeyra Therapeutics, Inc. reported that Board member Martin J. Joyce has decided not to stand for re-election at the company’s 2026 annual meeting of stockholders. He will continue to serve as a director until his term expires at that meeting.

The company stated that Mr. Joyce’s decision was not the result of any disagreement with Aldeyra, indicating an orderly and voluntary board transition rather than a dispute-driven departure.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

Board of Directors, 2026 annual meeting of stockholders, not stand for re-election, disagreement with Aldeyra

4 terms

Board of Directors financial

"Martin J. Joyce, a member of the Board of Directors of Aldeyra Therapeutics, Inc."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

2026 annual meeting of stockholders financial

"not stand for re-election at the upcoming 2026 annual meeting of stockholders"

not stand for re-election financial

"notified Aldeyra of his decision to not stand for re-election at the upcoming 2026 annual meeting"

disagreement with Aldeyra financial

"The decision by Mr. Joyce to not stand for re-election was not the result of any disagreement with Aldeyra."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Aldeyra Therapeutics (ALDX) disclose in this filing?

Aldeyra Therapeutics disclosed that director Martin J. Joyce will not stand for re-election at the 2026 annual meeting. He will continue serving on the Board until his current term expires at that meeting, indicating a planned and orderly transition in board composition.

When will Martin J. Joyce leave the Aldeyra Therapeutics (ALDX) Board?

Martin J. Joyce will remain a director until his term ends at Aldeyra Therapeutics’ 2026 annual meeting of stockholders. After that meeting, he will step down by not standing for re-election, so there is no immediate vacancy before the scheduled meeting date.

Did Martin J. Joyce resign from Aldeyra Therapeutics (ALDX) due to a disagreement?

No. Aldeyra Therapeutics specifically stated that Martin J. Joyce’s decision not to stand for re-election was not the result of any disagreement with the company. This suggests his departure reflects a voluntary choice rather than underlying conflict over company matters.

What type of event does this Aldeyra Therapeutics (ALDX) 8-K describe?

This 8-K describes a corporate governance event involving board composition at Aldeyra Therapeutics. It reports that director Martin J. Joyce will not seek re-election at the 2026 annual meeting, while confirming he will serve out his current term until that meeting.

Does Aldeyra Therapeutics (ALDX) face an immediate board vacancy from this change?

No immediate vacancy arises. Martin J. Joyce will continue serving on the Board of Directors until his term expires at the 2026 annual meeting. The company therefore has time to address future board composition before his seat becomes open after that meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/20/2026 - 05:00 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 20, 2026

ALDEYRA THERAPEUTICS, INC.

(Exact name of Registrant as specified in its charter)


Delaware	001-36332	20-1968197
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

131 Hartwell Avenue, Suite 320

Lexington, MA 02421

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (781) 761-4904

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	ALDX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     Item 5.02.

     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On April 20, 2026, Martin J. Joyce, a member of the Board of Directors of Aldeyra Therapeutics, Inc. (“Aldeyra”), notified Aldeyra of his decision to not stand for re-election at the upcoming 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Mr. Joyce will continue to serve until his term expires at the 2026 Annual Meeting. The decision by Mr. Joyce to not stand for re-election was not the result of any disagreement with Aldeyra.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated April 20, 2026


ALDEYRA THERAPEUTICS, INC.

By:	/s/ Todd C. Brady
	Name:	Todd C. Brady M.D., Ph.D.
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document